

TRACTATENBLAD

VAN HET

KONINKRIJK DER NEDERLANDEN

JAARGANG 2014 Nr. 21

A. TITEL

*Overeenkomst ter bestrijding van doping;
(met Bijlage)
Straatsburg, 16 november 1989*

B. TEKST

De Engelse en de Franse tekst van de Overeenkomst, met Bijlage, zijn geplaatst in *Trb.* 1991, 8.

Voor wijzigingen van de tekst van de Bijlage, zie rubriek J van *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44, *Trb.* 1997, 244, *Trb.* 1998, 104, *Trb.* 2001, 98, *Trb.* 2001, 185, *Trb.* 2003, 40, *Trb.* 2004, 194 en rubriek B van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 19, *Trb.* 2011, 274 en *Trb.* 2012, 243.

Voor enkele correcties zie *Trb.* 2008, 83 en *Trb.* 2009, 24.

De Commissie van Toezicht heeft tijdens haar 39^e vergadering op 14 november 2013, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, te Straatsburg een wijziging van de Bijlage aangenomen. De Engelse tekst van de wijziging luidt als volgt:

The 2014 prohibited list World Anti-Doping Code

Date of entry into force: 1 January 2014

In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and *Prohibited Methods* M1, M2 and M3.

*Substances and methods prohibited at all times
(in- and out-of-competition)*

Prohibited substances

S0. Non-approved substances

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1. Anabolic agents

Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)

a). Exogenous¹⁾ AAS, including:

1-androstenediol (5 α -androst-1-ene-3 β ,17 β -diol); 1-androstenedione (5 α - androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3 β ,17 β -diol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol); dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol); drostanolone; ethylestrenol (19-norpregna-4-en-17 α -ol); fluoxymesterone; formebolone; furazabol (17 α -methyl[1,2,5]oxadiazolo[3',4':2,3]-5 α -androst-17 β -ol); gestrinone; 4- hydroxytestosterone (4,17 β -dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); metenolone; methandriol; methasterone (17 β -hydroxy-2 α ,17 α - dimethyl-5 α -androst-3-one); methyl-dienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one); methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one); methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17 β - hydroxy-17 α -methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanazol (17 β -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α - androstane); quinbolone; stanozolol; stenbolone; 1-testosterone (17 β - hydroxy-5 α -androst-1-en-3-one); tetrahydrogestrinone (17-hydroxyestr-18 α -homo-19-nor-17 α -pregna-4,9,11-trien-

¹⁾ For purposes of this section: "Exogenous" refers to a substance which is not ordinarily produced by the body naturally.

3-one); trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s).

b) Endogenous²⁾ AAS when administered exogenously:

androstenediol (androst-5-ene-3 β ,17 β -diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17 β -hydroxy-5 α -androst-3-one); prasterone (dehydroepiandrosterone, DHEA, 3 β -hydroxyandrost-5-en-17-one); testosterone; and their metabolites and isomers, including but not limited to:

5 α -androstane-3 α ,17 α -diol; 5 α -androstane-3 α ,17 β -diol; 5 α -androstane-3 β ,17 α -diol; 5 α -androstane-3 β ,17 β -diol; androst-4-ene-3 α ,17 α -diol; androst-4-ene-3 α ,17 β -diol; androst-4-ene-3 β ,17 α -diol; androst-5-ene-3 α ,17 α -diol; androst-5-ene-3 α ,17 β -diol; androst-5-ene-3 β ,17 α -diol; 4-androstenediol (androst-4-ene-3 β ,17 β -diol); 5-androstenedione (androst-5-ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; etiocholanolone; 3 α -hydroxy-5 α -androst-17-one; 3 β -hydroxy-5 α -androst-17-one; 7 α -hydroxy-DHEA; 7 β -hydroxy-DHEA; 7-keto-DHEA; 19-norandrosterone; 19-noretiocholanolone.

2. Other Anabolic Agents, including but not limited to:

Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.

S2. Peptide hormones, growth factors and related substances

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoietin (dEPO), hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide)];

2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, in males;

3. Corticotrophins and their releasing factors;

4. Growth Hormone (GH) and its releasing factors and Insulin-like Growth Factor-1 (IGF-1).

In addition, the following growth factors are prohibited

Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilisation, regenerative capacity or fibre type switching;

²⁾ For purposes of this section: "Endogenous" refers to a substance which is ordinarily produced by the body naturally.

and other substances with a similar chemical structure or similar biological effect(s).

S3. Beta-2 agonists

All beta-2 agonists, including all optical isomers (e.g. *d*- and *l*-) where relevant, are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers' recommended therapeutic regime.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered an *Adverse Analytical Finding* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

S4. Hormone and metabolic modulators

The following are prohibited:

1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant.
4. Agents modifying myostatin function(s) including, but not limited to: myostatin inhibitors.
5. Metabolic modulators:
 - a) Insulins
 - b) Peroxisome Proliferator Activated Receptor δ (PPAR δ) agonists (e.g. GW 1516), PPAR δ -AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR)

S5. Diuretics and other masking agents

Masking agents are prohibited. They include:

Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid; and other substances with similar biological effect(s).

Local administration of felypressin in dental anaesthesia is not prohibited.

Diuretics include:

Acetazolamide, amiloride, bumetanide, canrenone, chlortalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, vaptans (e.g. tolvaptan); and other substances with a similar chemical structure or similar biological effect(s) (except for drospirenone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited).

The use *In-* and *Out-of-Competition*, as applicable, of any quantity of a substance subject to threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent.

Prohibited Methods

M1. Manipulation of blood and blood components

The following are prohibited:

1. The administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. Chemical and physical manipulation

The following are prohibited:

1. *Tampering*, or attempting to tamper, in order to alter the integrity and validity of *Samples* collected during *Doping Controls*. These include but are not limited to urine substitution and/or adulteration (e.g. proteases).
2. Intravenous infusions and/or injections of more than 50 mL per 6 hours period except for those legitimately received in the course of hospital admissions or clinical investigations.

M3. Gene doping

The following, with the potential to enhance sport performance, are prohibited:

1. The transfer of polymers of nucleic acids or nucleic acid analogues;
2. The use of normal or genetically modified cells.

Substances and methods prohibited in-competition

In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited *In-Competition*:

Prohibited substances

S6. Stimulants

All stimulants, including all optical isomers (e.g. *d*- and *l*-) where relevant, are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2014 Monitoring Program³.

Stimulants include:

a) Non-Specified Stimulants:

Adrafinil; amfepramone; amfetamine; amfetaminil; amiphenazole; benfluorex; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; fencamine; fenetylline; fenfluramine; fenproporex; fonturacetam [4-phenylpiracetam (carphedon)]; furfenorex; mefenorex; mephentermine; mesocarb; metamfetamine(*d*-); p-methylamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; prenylamine; prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

b) Specified Stimulants (examples):

Benzfetamine; cathine⁴; cathinone and its analogues (e.g. mephedrone, methedrone, α -pyrrolidinovalerophenone); dimethylamphetamine; ephedrine⁵; epinephrine⁶ (adrenaline); etamivan; etilamphetamine; etilefrine; famprofazone; fenbutrazate; fencamfamin; heptaminol; hydroxyamphetamine (parahydroxyamphetamine); isometheptene; levmetamphetamine; meclofenoxate; methylenedioxyamphetamine; methylephedrine⁷; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine (methyl-

³ The following substances included in the 2014 Monitoring Program (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, synephrine) are not considered as *Prohibited Substances*.

⁴ Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

⁵ Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

⁶ Local administration (e.g. nasal, ophthalmologic) of epinephrine (adrenaline) or co-administration with local anaesthetic agents is not prohibited.

⁷ Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

synephrine); pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine⁸⁾; selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine); trimetazidine; tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s).

S7. Narcotics

The following are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. Cannabinoids

Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and cannabimimetics (e.g. "Spice", JWH018, JWH073, HU-210) are prohibited.

S9. Glucocorticosteroids

All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

Substances prohibited in particular sports

P1. Alcohol

Alcohol (ethanol) is prohibited *In-Competition* only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.

- Air Sports (FAI)
- Archery (WA)
- Automobile (FIA)
- Karaté (WKF)
- Motorcycling (FIM)
- Powerboating (UIM)

⁸⁾ Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

P2. Beta-blockers

Unless otherwise specified, beta-blockers are prohibited *In-Competition* only, in the following sports.

- Archery (WA) (also prohibited *Out-of-Competition*)
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Shooting (ISSF, IPC) (also prohibited *Out-of-Competition*)
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air

Beta-blockers include, but are not limited to, the following:

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

C. VERTALING

Zie *Trb.* 1991, 8.

D. PARLEMENT

Zie *Trb.* 1995, 114.

E. PARTIJGEGEVENS

Zie *Trb.* 1991, 8, de rubrieken F en H van *Trb.* 1995, 114.

Partij	Onder-tekening	Ratificatie	Type [*]	In werking	Opzeg-ging	Buiten werking
Albanië	02-02-95	15-11-04	R	01-01-05		
Andorra	29-05-02	19-09-06	R	01-11-06		
Armenië	26-05-00	23-03-04	R	01-05-04		
Australië		05-10-94	T	01-12-94		
Azerbeidzjan	28-06-02	04-11-03	R	01-01-04		
Belarus	12-09-02	15-03-06	R	01-05-06		
België	16-11-89	30-11-01	R	01-01-02		

Partij	Onder-tekening	Ratificatie	Type*	In werking	Opzeg-ging	Buiten werking
Bosnië en Herzegovina		29-12-94	T	01-02-95		
Bulgarije	24-03-92	01-06-92	R	01-08-92		
Canada		06-03-96	O	01-05-96		
Cyprus	20-06-91	02-02-94	R	01-04-94		
Denemarken		16-11-89	O	01-03-90		
Duitsland	27-05-92	28-04-94	R	01-06-94		
Estland	14-05-93	20-11-97	R	01-01-98		
Finland	16-11-89	26-04-90	R	01-06-90		
Frankrijk	16-11-89	21-01-91	R	01-03-91		
Georgië	02-07-01	22-05-03	R	01-07-03		
Griekenland	10-10-90	06-03-96	R	01-05-96		
Hongarije		29-01-90	O	01-03-90		
Ierland	25-06-92	29-01-03	R	01-03-03		
IJsland		25-03-91	O	01-05-91		
Italië	16-11-89	12-02-96	R	01-04-96		
Joegoslavië (< 25-06-1991)	10-07-91	10-07-91	R	01-09-91		
Kroatië		27-01-93	T	01-03-93		
Letland	23-01-97	23-01-97	R	01-03-97		
Liechtenstein	16-11-89	22-05-00	R	01-07-00		
Litouwen	01-04-93	17-05-96	R	01-07-96		
Luxemburg	16-11-89	21-06-96	R	01-08-96		
Macedonië, de voormalige Joegoslavische Republiek		30-03-94	T	01-05-94		
Malta	09-09-94	03-11-11	R	01-01-12		
Marokko		19-06-13	T	01-10-13		
Moldavië	20-02-08	27-01-09	R	01-03-09		

Partij	Onder- tekening	Ratificatie	Type*	In werking	Opzeg- ging	Buiten werking
Monaco	09-09-03	28-11-03	R	01-01-04		
Montenegro		14-06-06	VG	06-06-06		
Nederlanden, het Koninkrijk der – Nederland: – in Europa – Bonaire – Sint Eustatius – Saba – Aruba – Curaçao – Sint Maarten	04-12-90	11-04-95 – – – – –	R	01-06-95 10-10-10 10-10-10 10-10-10 – 10-10-10 10-10-10		
Noorwegen		16-11-89	O	01-03-90		
Oekraïne	02-07-98	29-11-01	R	01-01-02		
Oostenrijk	10-05-90	10-07-91	R	01-09-91		
Polen	16-11-89	07-09-90	R	01-11-90		
Portugal	14-06-90	17-03-94	R	01-05-94		
Roemenië	16-06-94	07-12-98	R	01-02-99		
Russische Federatie		12-02-91	T	01-04-91		
San Marino	16-11-89	31-01-90	R	01-03-90		
Servië		28-02-01	T	01-04-01		
Slovenië		02-07-92	T	01-09-92		
Slowakije		06-05-93	O	01-07-93		
Spanje	16-11-89	20-05-92	R	01-07-92		
Tsjechië		28-04-95	O	01-06-95		
Tunesië		26-02-04	T	01-04-04		
Turkije	16-11-89	22-11-93	R	01-01-94		
Verenigd Koninkrijk		16-11-89	O	01-03-90		
Zweden	16-11-89	29-06-90	R	01-08-90		
Zwitserland	16-11-89	05-11-92	R	01-01-93		

Partij	Onder- tekening	Ratificatie	Type*	In werking	Opzeg- ging	Buiten werking
* O=Ondertekening zonder voorbehoud of vereiste van ratificatie, R= Bekrachtiging, aanvaarding, goedkeuring of kennisgeving, T=Toetreding, VG=Voortgezette gebondenheid, NB=Niet bekend						

Uitbreidingen

Frankrijk

Uitgebreid tot	In werking	Buiten werking
Bassas da India	01-03-1991	
Clipperton	01-03-1991	
Europa-eiland	01-03-1991	
Frans Guyana	01-03-1991	
Frans-Polynesië	01-03-1991	
Franse Zuidelijke en Zuidpoolgebieden	01-03-1991	
Glorioso-eilanden	01-03-1991	
Guadeloupe	01-03-1991	
Juan de Nova-eiland	01-03-1991	
Martinique	01-03-1991	
Mayotte	01-03-1991	
Nieuw Caledonië	01-03-1991	
Réunion	01-03-1991	
Sint Pierre en Miquelon	01-03-1991	
Tromelin	01-03-1991	
Wallis en Futuna	01-03-1991	

Verenigd Koninkrijk

Uitgebreid tot	In werking	Buiten werking
Man	01-11-1993	

Verklaringen, voorbehouden en bezwaren

Denemarken, 16 november 1989

Until further notice the signature of Denmark of this Convention does not engage Greenland and the Faroe Islands.

Griekenland, 7 juli 1994

The Government of the Hellenic Republic declares that the accession of the Former Yugoslav Republic of Macedonia to the Conventions of the Council of Europe to which the Hellenic Republic is a Contracting Party does not imply the recognition of the Former Yugoslav Republic of Macedonia by the Hellenic Republic.

Moldavië, 27 januari 2009

Until the full re-establishment of the territorial integrity of the Republic of Moldova, the provisions of the Convention will be applied only on the territory controlled effectively by the authorities of the Republic of Moldova.

G. INWERKINGTREDING

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, rubriek J van *Trb.* 1996, 284, *Trb.* 1997, 244, *Trb.* 1998, 104, *Trb.* 2001, 98, *Trb.* 2001, 185, *Trb.* 2003, 40 en *Trb.* 2004, 194, en rubriek G van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 19, *Trb.* 2011, 274 en *Trb.* 2012, 243.

De wijziging van de Bijlage bij de Overeenkomst van 14 november 2013 is op 1 januari 2014 in werking getreden voor alle partijen bij de Overeenkomst, waaronder het Koninkrijk der Nederlanden.

Wat betreft het Koninkrijk der Nederlanden, geldt de wijziging van de Bijlage, evenals de Overeenkomst, voor Nederland (het Europese en het Caribische deel), Curaçao en Sint-Maarten.

J. VERWIJZINGEN

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44, *Trb.* 2004, 194, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 274 en *Trb.* 2012, 243.

Verbanden

Titel : Internationaal Verdrag tegen doping in de sport;
Parijs, 19 oktober 2005
Laatste *Trb.* : *Trb.* 2013, 189

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van de Bijlage van 14 november 2013 zal zijn bekendgemaakt in Nederland (het Europese en het Caribische deel), Curaçao en Sint Maarten op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de *dertigste* januari 2014.

De Minister van Buitenlandse Zaken,

F.C.G.M. TIMMERMANS